Mutant p53 proteins behave in a dominant, negative fashion in vivo - PubMed (original) (raw)
. 1994 Sep-Oct;14(5A):1853-9.
Affiliations
- PMID: 7847818
Mutant p53 proteins behave in a dominant, negative fashion in vivo
M Hachiya et al. Anticancer Res. 1994 Sep-Oct.
Abstract
The p53 encodes a cellular phosphoprotein that has been association with both neoplastic transformation and the control of cellular growth. Recent studies have reported that p53 also acts as a transcriptional regulator. We have studied transactivational properties of human wild-type and mutant p53 proteins representing 4 major mutational hotspots (codons 141, 175, 248, 273) as well as a double mutant Tyr141/His273 and a p53 with the transcriptional activating region removed (pcDC2). Transactivation by p53 was shown with a p53 concensus binding sequence controlled CAT reporter gene, and activity was assayed after co-transfection of the reporter with either wild-type or mutant p53 expression constructs. Wild-type p53 as well as one mutant p53 [(mutation of arginine to histidine at codon 273 (His 273)], had strong transactivating activity, but all other mutant p53s were inactive in transcriptional activation, including the double mutant Tyr141/His273 suggesting that the Tyr141 mutation was dominant over the His273 mutation in the same protein. Moreover, when mutant p53 (Tyr141, His175, Trp248, or Tyr141/His273) was cotransfected with either wild-type p53 or mutant His273 p53, these mutants inhibited the transactivation of coexpressed wild-type p53. The p53 vector (pcDC2), which contains p53 oligomerization sequences, but not the transactivational domain, markedly inhibited wild-type p53 transactivational activity. Each of the mutant p53s similarly inhibited the transactivation of His273 p53. Therefore, with the exception of His273, each of the other mutant p53 were unable to transactivate and each behaved in a dominant negative fashion.
Similar articles
- Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP. Park DJ, et al. Oncogene. 1994 Jul;9(7):1899-906. Oncogene. 1994. PMID: 8208536 - Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM, Miller CW, Chen DL, Koeffler HP. Chumakov AM, et al. Oncogene. 1993 Nov;8(11):3005-11. Oncogene. 1993. PMID: 8414502 - p53 transactivation through various p53-responsive elements.
Park DJ, Chumakov AM, Miller CW, Pham EY, Koeffler HP. Park DJ, et al. Mol Carcinog. 1996 Jun;16(2):101-8. doi: 10.1002/(SICI)1098-2744(199606)16:2<101::AID-MC6>3.0.CO;2-L. Mol Carcinog. 1996. PMID: 8645424 - Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E, Deppert W. Kim E, et al. J Cell Biochem. 2004 Nov 15;93(5):878-86. doi: 10.1002/jcb.20271. J Cell Biochem. 2004. PMID: 15449312 Review. - [Dominant negative activity of mutated p53 proteins].
Dridi W, Krabchi K, Gadji M, Lavoie J, Bronsard M, Fetni R, Drouin R. Dridi W, et al. Med Sci (Paris). 2006 Mar;22(3):301-7. doi: 10.1051/medsci/2006223301. Med Sci (Paris). 2006. PMID: 16527213 Review. French.
Cited by
- Double mutant fibrillin-1 (FBN1) allele in a patient with neonatal Marfan syndrome.
Wang M, Kishnani P, Decker-Phillips M, Kahler SG, Chen YT, Godfrey M. Wang M, et al. J Med Genet. 1996 Sep;33(9):760-3. doi: 10.1136/jmg.33.9.760. J Med Genet. 1996. PMID: 8880577 Free PMC article. - Cellular players in the herpes simplex virus dependent apoptosis balancing act.
Nguyen ML, Blaho JA. Nguyen ML, et al. Viruses. 2009 Dec;1(3):965-78. doi: 10.3390/v1030965. Epub 2009 Nov 18. Viruses. 2009. PMID: 21994577 Free PMC article. - p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.
Di Como CJ, Gaiddon C, Prives C. Di Como CJ, et al. Mol Cell Biol. 1999 Feb;19(2):1438-49. doi: 10.1128/MCB.19.2.1438. Mol Cell Biol. 1999. PMID: 9891077 Free PMC article. - p53: the attractive tumor suppressor in the cancer research field.
Ozaki T, Nakagawara A. Ozaki T, et al. J Biomed Biotechnol. 2011;2011:603925. doi: 10.1155/2011/603925. Epub 2010 Dec 6. J Biomed Biotechnol. 2011. PMID: 21188172 Free PMC article. Review. - How many mutant p53 molecules are needed to inactivate a tetramer?
Chan WM, Siu WY, Lau A, Poon RY. Chan WM, et al. Mol Cell Biol. 2004 Apr;24(8):3536-51. doi: 10.1128/MCB.24.8.3536-3551.2004. Mol Cell Biol. 2004. PMID: 15060172 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous